Results 161 to 170 of about 56,351 (295)
Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies. [PDF]
DiseasesAfonso S +6 more
europepmc +1 more source
British Journal of Pharmacology, Volume 183, Issue 7, Page 1517-1538, April 2026.Abstract Background and Purpose Alarming trends show that vaping e‐cigarettes containing synthetic cannabinoid receptor agonists, such as JWH‐018, is increasing among youth. However, the effects of these trends are unclear in both sexes. We therefore characterized the neuropharmacological effects of adolescent JWH‐018 inhalation in male and female rats.
Nicholas Pintori +7 more
wiley +1 more source
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies. [PDF]
CellsWen J, Zhang Y.
europepmc +1 more source
Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
International Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska +8 more
wiley +1 more source
Bridging the Regulatory Chasm in Investigator‐Initiated Human Subject Cannabis Research
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 834-837, April 2026.
Heather M. Barkholtz, William Naviaux
wiley +1 more source
New Phytologist, Volume 250, Issue 2, Page 762-787, April 2026.Summary B‐box (BBX) proteins were initially characterized as transcription factors connecting light signaling to the regulation of flowering time and seedling photomorphogenesis. However, over the last decade, increasing evidence has shown that they integrate light and hormone signaling, modulating multiple physiological processes during plant life. In
Bruno Silvestre Lira +3 more
wiley +1 more source
Effects of Cannabidiol on TAFAZZIN‐Deficient B‐Lymphoblastoid Cells
The FASEB Journal, Volume 40, Issue 6, 31 March 2026.Deficiency of the cardiolipin remodeling enzyme TAFAZZIN causes Barth syndrome (BTHS), resulting in cardiolipin loss, monolysocardiolipin (MLCL) accumulation, and electron transport chain (ETC) abnormalities in B‐lymphoblastoid cells. Effects of the non‐psychotropic phytocannabinoid cannabidiol (CBD) were examined on B‐lymphoblastoid cells from ...
John Z. Chan +10 more
wiley +1 more source
International Journal of Quantum Chemistry, Volume 126, Issue 5, March 5, 2026.Cannabidiol (CBD) exhibits increased reactivity, stronger CB1 receptor binding, and enhanced cytotoxicity against A431 squamous carcinoma cells compared to 5‐fluorouracil (5‐FU). Integrated DFT, molecular docking, and experimental analyses demonstrate CBD's improved stability and binding affinity, highlighting its potential as an alternative ...
Andrea Jess Josiah +5 more
wiley +1 more source
Melatonin mitigates hormonal toxicity in cannabis-treated female Wistar rats: involvement of cannabinoid receptor. [PDF]
J Cannabis ResOluwasola A.
europepmc +1 more source